SIO CAPITAL MANAGEMENT LLC
Q3 2022 Form 13-F

NEW YORK, NEW YORK
CIK 0001482416 · CRD 165989 · SEC-registered investment adviser
$314.7M Reported Value Total

SIO CAPITAL MANAGEMENT, LLC reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $1,065,063,194, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
6 funds · $864.7M gross asset value
Hedge Fund: $864.7M
Source: Form ADV filed 2026-03-18
Reported value
$314.7M
Quarter over quarter
-2.6%
Holdings
43
Top-10 concentration
69.9%

Key People

Form ADV owners & control persons
Michael Bernard Castor
MANAGING MEMBER
Judah Zvi Drillick
CHIEF EXECUTIVE OFFICER
Jin Woo Lee
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2022 13F record

Q3 2022 13F filing summary

Q3 2022 Form 13F portfolio summary
Period of report September 30, 2022
Filed November 14, 2022
Form 13F-HR
Reported value $314.7M
Positions 43
Change in reported value +18.2%
New positions 4
Exited positions 20
Position turnover 38.1%
Top-10 concentration 69.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
51 $528.5M
Q2 2026 13F
Filed Aug 14, 2026
57 $604.3M
Q1 2026 13F
Filed May 14, 2026
73 $697.3M
Q4 2025 13F
Filed Feb 17, 2026
65 $635.7M
Q3 2025 13F
Filed Nov 13, 2025
51 $395.2M
Q2 2025 13F
Filed Aug 13, 2025
49 $261.8M
Q1 2025 13F
Filed May 15, 2025
53 $335.8M
Q4 2024 13F
Filed Feb 14, 2025
51 $355.4M
Q3 2024 13F
Filed Nov 14, 2024
38 $252.2M
Q2 2024 13F
Filed Aug 14, 2024
46 $369.5M
Q1 2024 13F
Filed May 15, 2024
48 $335.8M
Q4 2023 13F
Filed Feb 13, 2024
39 $439.2M
Q3 2023 13F
Filed Nov 14, 2023
52 $323.1M
Q2 2023 13F
Filed Aug 14, 2023
41 $393.2M
Q1 2023 13F
Filed May 12, 2023
44 $202.3M
Q4 2022 13F
Filed Feb 13, 2023
41 $270.4M
Q3 2022 13F
Filed Nov 14, 2022
43 $314.7M
Q2 2022 13F
Filed Aug 15, 2022
59 $266.2M
Q1 2022 13F
Filed May 16, 2022
61 $302.3M
Q4 2021 13F
Filed Feb 14, 2022
67 $331.7M

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2022

Largest Q3 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 COR AMERISOURCEBERGEN CORP $38.2M 12.14%
2 APLS P APELLIS PHARMACEUTICALS INC $34.7M 11.02%
3 GSK GSK PLC $23.3M 7.39%
4 MSAC MEDICUS SCIENCES ACQUISITION $23.0M 7.31%
5 RLMD P RELMADA THERAPEUTICS INC $22.4M 7.13%
6 RXDX P PROMETHEUS BIOSCIENCES INC $19.6M 6.23%
7 BCYC BICYCLE THERAPEUTICS PLC $15.9M 5.05%
8 OGN ORGANON & CO $14.7M 4.68%
9 CI CIGNA CORP $14.6M 4.64%
10 SNY SANOFI SA $13.6M 4.31%
11 INGN INOGEN INC $12.7M 4.02%
12 CNC CENTENE CORP DEL $9.9M 3.14%
13 UTHR UNITED THERAPEUTICS CORP $9.4M 2.99%
14 SKIN THE BEAUTY HEALTH CO $7.8M 2.47%
15 SNN SMITH & NEPHEW PLC $5.3M 1.69%
16 VNDA VANDA PHARMACEUTICALS INC $4.8M 1.54%
17 PNT POINT BIOPHARMA GLOBAL INC $4.2M 1.34%
18 NARI INARI MEDICAL INC $4.2M 1.33%
19 UHS UNIVERSAL HEALTH SERVICES INC $3.6M 1.14%
20 EUCRU EUCRATES BIOMEDICAL ACQUISITION CORP. $2.5M 0.79%

Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings